A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

The US Food and Drug Administration (FDA) announces new regulatory guidelines for future COVID-19 vaccines and booster shots.

The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine, but with unusual ...

The U.S. Food and Drug Administration (FDA) announced new regulatory guidelines for COVID-19 vaccine boosters on Tuesday, ...

Shares of vaccine makers saw an uptick in the latest trading session, with Moderna Inc (BMV:MRNA). (NASDAQ:MRNA) leading the ...

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

Over the past weekend, the new CEO of UnitedHealth (UNH) bought shares after the sell-off. UNH stock gained 8.21% to close at ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

The US Food and Drug Administration (FDA) has granted full approval to Novavax’s COVID-19 vaccine, but only for certain people.

Novavax makes the nation’s only traditional protein-based coronavirus vaccine – and until now it had emergency authorization ...

JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This ...

Live Updates Live Coverage Has Ended Markets Turn Positive 1:37 pm by The stock market has managed to crawl its way back ...